Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

@article{Miller2005RandomizedPI,
  title={Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.},
  author={Kathy D. Miller and Linnea I. Chap and Frankie Ann Holmes and Melody A. Cobleigh and Paul Kelly Marcom and Louis Fehrenbacher and Maura N. Dickler and Beth A Overmoyer and James Dennis Reimann and Amy Pratt Sing and Virginia K. Langmuir and Hope S Rugo},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2005},
  volume={23 4},
  pages={
          792-9
        }
}
PURPOSE This randomized phase III trial compared the efficacy and safety of capecitabine with or without bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. PATIENTS AND METHODS Patients were randomly assigned to receive capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks, alone or in combination with bevacizumab (15 mg/kg) on day 1. The primary end… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 585 CITATIONS

Manual of Cardio-oncology

  • Springer International Publishing
  • 2017
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 4 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials.

  • Cancer treatment reviews
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The VEGF pathway in cancer and disease: responses, resistance, and the path forward.

  • Cold Spring Harbor perspectives in medicine
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1992
2019

CITATION STATISTICS

  • 39 Highly Influenced Citations

  • Averaged 26 Citations per year over the last 3 years

Similar Papers

Loading similar papers…